drugset / Trial / NCT07704658
Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors
NaSingle-groupOpen-labelOther
Summary
An open-label drug-drug interaction study to evaluate the effects of pralsetinib (Gavreto) on the pharmacokinetics of a CYP450 probe substrate cocktail and, in female participants, a hormonal probe substrate, in participants with rearranged during transfection (RET) fusion- or mutation-positive solid tumors
Timeline
- Start
- 2026-06
- Primary completion
- 2027-07-30
- Completion
- 2027-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Estradiol/norethisterone acetate | Unknown | — | Oral |
| Subject | Losartan | Other / unclassified | — | Oral |
| Subject | Midazolam | Small molecule | — | Oral |
| Subject | Pralsetinib | Small molecule | 400 mg | Oral |
| Subject | Repaglinide | Small molecule | — | Oral |